All In MedTech

Device Trial Radar · NCT06754046

BELIEVE Trial: Bulking vErsus sLing for Treating Stress Urinary IncontinEnce at the Time of Vaginal prolapsE Repair (BELIEVE)

BELIEVE Trial: Bulking vErsus sLing for Treating Stress Urinary IncontinEnce at the Time of Vaginal prolapsE Repair

Last checked: Nov 19, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 476 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

476

Planned (sponsor's estimate)

Start

May 1, 2025

Primary completion

Apr 2029

Study completion Apr 2029

Sponsor

Lead sponsor
University Hospitals Cleveland Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Kaiser Permanente; Duke University; Patient-Centered Outcomes Research Institute; University of California, San Diego; University of California, Irvine; MetroHealth Medical Center; Ohio State University; Northwestern University; University of New Mexico; Medstar Health Research Institute; University of Michigan
First posted
Dec 31, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if retropubic midurethral sling (RP-MUS) or bulkamide injection (PAHG) at the time of pelvic organ prolapse repair is better from the patient's perspective. The main questions it aims to answer are: What is the average difference in the urogenital distress inventory (UDI) long form score 24 months after surgery for each procedure? Which procedure has the fewest complications and lowest short- and long-term morbidity profile? Participants will: Be blinded and randomized to one of two procedures for the duration of the study, 24 months. Complete 6 total visits for the clinical trial including validated questionnaires. Few participants will be selected to complete a qualitative interview at 3 timepoints over 24 month duration of the study.

Conditions

  • Stress Urinary Incontinence
  • Vaginal Prolapse

Interventions

  • RP-MUSDevice

    a standard urethral sling placement for treatment of stress urinary incontinence

  • PAHGProcedure

    A standard 2 mL dose injection of bulkamid (order and number will be at the discretion of the surgeon) will be given. Patients undergoing PAHG will be given sham incisions consisting of superficial suprapubic epidermal scratches with a needle and fibrin glue at expected sling exit sites.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Bothersome stress urinary incontinence symptoms as measured by urogenital distress inventory long form (UDI)Time frame: 24 months postoperatively

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.